Financials in USD. Standardized financial statements.
A compact view of how Sangui Biotech International, Inc. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $133,345 | $93,039 | $69,190 | $65,585 | $28,915 | $88,000 | $77,152 | $67,653 | $48,009 | $127,469 |
| Revenue Growth? | +43.3% | +34.5% | +5.5% | +126.8% | -67.1% | +14.1% | +14.0% | +40.9% | -62.3% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 | $0 | $0 | $62 | $693 | $293 | $532 |
| Gross Profit? | $133,345 | $93,039 | $69,190 | $65,585 | $28,915 | $88,000 | $75,484 | $66,960 | $47,716 | $126,937 |
| Gross Margin? | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +97.8% | +99.0% | +99.4% | +99.6% |
| Operating Expenses? | $135,140 | $181,121 | $208,636 | $216,723 | $210,309 | $425,636 | $285,135 | $383,759 | $408,620 | $879,272 |
| Operating Income? | -$1,795 | -$88,082 | -$139,446 | -$151,138 | -$181,394 | -$337,635 | -$208,045 | -$316,799 | -$360,904 | -$752,335 |
| EBITDA? | -$1,439 | -$87,726 | -$22,475 | -$165,242 | -$180,185 | -$330,828 | -$207,496 | -$316,799 | -$360,904 | -$752,299 |
| Income Before Tax | -$8,087 | -$147,713 | -$63,342 | -$198,890 | -$198,526 | -$342,514 | -$215,803 | -$329,606 | -$446,360 | -$758,408 |
| Income Tax Expense | $0 | $0 | $0 | $32,267 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$12,140 | -$147,721 | -$59,310 | -$235,977 | -$192,741 | -$323,576 | -$201,810 | -$308,980 | -$422,271 | -$704,703 |
| EPS? | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 |
| Diluted EPS? | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality